Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial

Diabetes Technology&Therapeutics,Volume 22, Issue 7, Page 516-526, July 2020.
Source: Diabetes Technology - Category: Endocrinology Authors: Source Type: research